The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key challenges, including a lack of data in CD and opportunities to improve access to treatment.
The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key challenges, including a lack of data in CD and opportunities to improve access to treatment. | Image credit: sdecoret - stock.adobe.com
CD, under the category of inflammatory bowel disease (IBD), is a chronic inflammatory condition of the gastrointestinal tract. The advanced therapeutic options for moderate to severe CD, biologics targeting tumor necrosis factor (TNF)-α (infliximab, adalimumab, and certolizumab), integrins (vedolizumab and natalizumab), and interleukins (ustekinumab), have become “the primary financial burden associated with IBD management,” the authors said.
Ustekinumab is a monoclonal antibody targeting the p40 subunit of interleukin (IL)-12 and IL-23. The reference product (Stelara) was first approved by the FDA and European Medicines Agency (EMA) in 2009. Both agencies approved ustekinumab for treating CD in 2016.
Ustekinumab can be used in biologic-naive patients and those who have had treatment failure on another biologic. However, the authors said that due to high costs, ustekinumab is usually reserved for situations in which a patient has had treatment failure on 1 or more anti-TNF biologics. The originator’s patent is nearing expiration, which opens the possibility of ustekinumab biosimilars that could reduce costs, increase access to therapy, and allow for earlier use of ustekinumab in the course of CD treatment.
“Robust evidence” shows that anti-TNF biosimilars are clinically equivalent to the reference product (Humira), the reviewers said. For ustekinumab biosimilars, comparable efficacy, safety, immunogenicity, and pharmacokinetics to the reference product have been demonstrated; however, their approval for CD is based on extrapolation, “and there is no real-world data available yet for this indication.”
The first ustekinumab biosimilar, ABP 654 (Wezlana), was approved by the FDA in November 2023. AVT04 (Uzpruvo) was approved by the EMA and FDA in 2024, making it the first ustekinumab biosimilar approved in Europe. Additional ustekinumab biosimilars are in development. For example, Celltrion’s CT-P43 is supported by a phase 3 randomized controlled trial (RCT) showing comparable efficacy to the originator in moderate-to-severe plaque psoriasis. Marketing authorization applications for Dong-A ST's DMB-311535 and Fresenius Kabi and Formycon's FYB20236 have been accepted by the EMA and will soon be entering the market.
Overall, according to the reviewers, ustekinumab biosimilars have shown similar pharmacokinetic features, safety profiles, efficacy, and immunogenicity compared to the reference product in studies on healthy subjects and those on patients with psoriasis. Real-world studies could “increase the confidence of gastroenterologists when adopting ustekinumab biosimilars to treat CD patients.”
The authors commented that although there are several biologics available, there is no “globally validated therapeutic algorithm” for treating patients with moderate to severe CD. TNF inhibitors are “generally considered the first-line therapy as they are safe and effective drugs and biosimilars are available which make them accessible.” However, a trial comparing ustekinumab and adalimumab found they were equally effective in patients with CD, and a better safety profile, tolerability, and persistence were observed for ustekinumab. “Based on these data, ustekinumab could emerge as a leading choice in CD,” the reviewers said.
Additional recently approved treatment options for CD therapy include the IL-23 inhibitor risankizumab. One trial found risankizumab superior to ustekinumab for achieving endoscopic remission in patients with CD who were previously treated with anti-TNF biologics, but another found no differences between mirikizumab and ustekinumab effectiveness in CD. The reviewers said more head-to-head trials will be necessary “to define the positioning of selective IL-23 inhibitors” in CD treatment. Since risankizumab biosimilars are not yet available, among IL-23 inhibitors, ustekinumab biosimilars have a cost advantage.
The reviewers concluded that ustekinumab biosimilars “could be considered as first-line therapy for patients with IBD requiring advanced treatment,” increasing access and changing the drug’s positioning in the CD treatment algorithm. They added that real-world studies of ustekinumab biosimilars in IBD are needed to confirm long-term safety data.
Reference
D'Amico F, Bencardino S, Gonçalves A, Allocca M, Furfaro F, Zilli A, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment. United European Gastroenterol J. 2025;13(2):186-200. doi:10.1002/ueg2.12682
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.